In addition, AKIRIN2 participates in the regulation of chemotherapy sensitivity of glioma [36], chronic myelogenous leukaemia [37], and ovarian cancer [38]. This evidence concerns the gene AKIRIN2 and chronic myelogenous leukemia, BCR-ABL1 positive.